Table 3.
Median survival of immunocompetent mice bearing subcutaneous myeloma tumors after administration of recombinant VSV without or with 131I
| Treatment | Mice per group | Median survival, d |
P compared with |
|
|---|---|---|---|---|
| PBS | Respective rVSV construct | |||
| PBS | 4 | 20.0 | — | — |
| PBS + 131I | 4 | 20.0 | NS | — |
| VSV(Δ51)-NIS, intratumorally | 6 | 30.0 | .002 | .213 |
| VSV(Δ51)-NIS, intratumorally + 131I | 6 | 32.0 | .002 | — |
| VSV(Δ51)-NIS, intravenously | 6 | 28.5 | .002 | .018 |
| VSV(Δ51)-NIS, intravenously + 131I | 6 | 35.0 | .002 | — |
| VSV(Δ51)-GFP, intratumorally | 4 | 28.5 | .01 | NS |
| VSV(Δ51)-GFP, intratumorally + 131I | 4 | 28.5 | .01 | — |
rVSV was administered on days 12 and 13 after tumor cell inoculation. 131I was given intraperitoneally on day 14. Kaplan-Meier survival curves were drawn.
NS indicates not significant; —, not applicable.